Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Recommendation of “Buy” from Analysts

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $7.83.

Several equities analysts have issued reports on the stock. Piper Sandler assumed coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price on the stock. Raymond James assumed coverage on shares of Aquestive Therapeutics in a research note on Thursday, March 28th. They set an “outperform” rating and a $7.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, June 26th. Leerink Partnrs upgraded shares of Aquestive Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. Finally, SVB Leerink assumed coverage on shares of Aquestive Therapeutics in a research note on Friday, May 10th. They set an “outperform” rating and a $8.00 target price on the stock.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $2.48 on Friday. The stock has a market cap of $225.78 million, a price-to-earnings ratio of -5.90 and a beta of 2.80. The firm’s 50-day moving average is $2.93 and its 200 day moving average is $3.20. Aquestive Therapeutics has a 1 year low of $1.25 and a 1 year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). The company had revenue of $12.05 million for the quarter, compared to the consensus estimate of $12.22 million. During the same quarter last year, the firm posted $0.11 EPS. On average, equities analysts expect that Aquestive Therapeutics will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several institutional investors have recently made changes to their positions in the business. Virtu Financial LLC lifted its stake in shares of Aquestive Therapeutics by 219.7% in the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock worth $438,000 after purchasing an additional 70,666 shares during the period. Lazard Asset Management LLC increased its holdings in Aquestive Therapeutics by 115.5% in the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares in the last quarter. Vanguard Group Inc. increased its holdings in Aquestive Therapeutics by 71.7% in the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $54,000. Finally, Janney Montgomery Scott LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $1,456,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.